In Reply:
- 1 October 2003
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (19), 3709-3710
- https://doi.org/10.1200/jco.2003.99.134
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Fludarabine-Related Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011Journal of Clinical Oncology, 2002
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood, 2002
- Epstein–Barr Virus-Positive B-Cell Lymphoproliferative Disorders Arising in Immunodeficient Patients Previously Treated With Fludarabine for Low-Grade B-Cell NeoplasmsThe American Journal of Surgical Pathology, 2002
- Aggressive growth of epithelial carcinomas following treatment with nucleoside analoguesAmerican Journal of Hematology, 2002
- Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphomaAnnals Of Oncology, 2002
- Large‐cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine–rituximab‐containing regimens: natural history‐ or therapy‐related complication?European Journal of Haematology, 2002
- Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphomaLeukemia Research, 2000
- Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial TherapyBlood, 1998